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Abstract
WNT-5A, a key player in embryonic development and post-natal homeostasis, has been associated with a myriad of
pathological conditions including malignant, fibroproliferative and inflammatory disorders. Previously, we have identified
WNT-5A as a transcriptional target of TGF-b in airway smooth muscle cells and demonstrated its function as a mediator of
airway remodeling. Here, we investigated the molecular mechanisms underlying TGF-b-induced WNT-5A expression. We
show that TGF-b-activated kinase 1 (TAK1) is a critical mediator of WNT-5A expression as its pharmacological inhibition or
siRNA-mediated silencing reduced TGF-b induction of WNT-5A. Furthermore, we show that TAK1 engages p38 and c-Jun N-
terminal kinase (JNK) signaling which redundantly participates in WNT-5A induction as only simultaneous, but not
individual, inhibition of p38 and JNK suppressed TGF-b-induced WNT-5A expression. Remarkably, we demonstrate a central
role of b-catenin in TGF-b-induced WNT-5A expression. Regulated by TAK1, b-catenin is required for WNT-5A induction as its
silencing repressed WNT-5A expression whereas a constitutively active mutant augmented basal WNT-5A abundance.
Furthermore, we identify Sp1 as the transcription factor for WNT-5A and demonstrate its interaction with b-catenin. We
discover that Sp1 is recruited to the WNT-5A promoter in a TGF-b-induced and TAK1-regulated manner. Collectively, our
findings describe a TAK1-dependent, b-catenin- and Sp1-mediated signaling cascade activated downstream of TGF-b which
regulates WNT-5A induction.
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Introduction
WNT-5A is a member of the Wingless/integrase 1 (WNT)
family of secreted glycoproteins. There are 19 WNT ligands
known in humans that act through 10 Frizzled (FZD) receptors,
low-density lipoprotein receptor-related protein (LRP) 5/6 co-
receptors and many non-FZD receptors, including ROR1, ROR2,
RYK [1]. WNT signaling is broadly subdivided into two main
streams- canonical (b-catenin-dependent) and non-canonical (b-
catenin-independent) WNT signaling. In the canonical signaling,
binding of a WNT ligand to a FZD receptor and LRP5/6 co-
receptors activates signaling mechanisms resulting in stabilization
of the transcriptional co-activator b-catenin, leading to its
accumulation in the cytosol. Stabilized b-catenin translocates to
the nucleus where it partners with the T-cell factor/lymphoid
enhancer-binding factor (TCF/LEF) transcription factors and
activates target gene transcription. Non-canonical WNT signaling
functions exclusive of b-catenin and LRP5/6 and involves a
multitude of pathways regulating gene transcription, cytoskeletal
reorganization, cell polarity and cell movements. WNT/Ca2+ and
WNT/planar cell polarity (PCP) are the best characterized non-
canonical WNT signaling pathways among others. In the WNT/
Ca2+ signaling, binding of WNT ligands to FZD or non-FZD
receptors activates calcium-dependent signaling molecules, includ-
ing protein kinase C (PKC), Ca2+/calmodulin-dependent protein
kinase II (CaMKII) and nuclear factor of activated T-cell (NFAT),
whereas the WNT/PCP pathway involves activation of the RhoA
signaling or c-Jun N-terminal Kinases (JNKs) via small Rho-
GTPases [1].
WNT-5A is a crucial signaling molecule which primarily acts
through non-canonical WNT signaling and plays key roles in
embryonic development and post-natal homeostatic processes
[2,3]. It is involved in lung [4], heart [5] and mammary gland
morphogenesis [6] and regulates stem cell renewal and tissue
regeneration [7,8]. In parallel, WNT-5A has been linked to
inflammation [9] and various malignancies [10].
Furthermore, WNT-5A has been very closely associated with
fibrosis. Increased amount of WNT-5A is reported in lung
fibroblasts of pulmonary fibrosis patients where it regulates
proliferation and promotes cell viability [11]. Similarly, studies
have implicated WNT-5A expression and signaling in renal [12]
and hepatic [13] fibrosis. WNT-5A signaling has also been
implicated in ciliopathies [14] and WNT-5A antagonism has been
shown to counteract vascular calcification [15].
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We have recently reported increased WNT-5A expression in
asthmatic airway smooth muscle cells [16]. We have shown that
TGF-b induces WNT-5A expression in airway smooth muscle
cells where it mediates the expression of extracellular matrix
proteins (ECM) [16]. TGF-b also induces WNT-5A expression in
pancreatic cancer cells [17]. Similarly, the pro-inflammatory
cytokines-IL-1b [18], TNF-a [19], LPS/IFNc [20], IL-6 family
members- leukemia inhibitory factor (LIF) and cardiotrophin-1
(CTF-1) [21] and high extracellular Ca2+ concentration [22] have
also been shown to augment WNT-5A expression in various cell
types.
While our knowledge about the involvement of WNT-5A in
various physiological and pathological processes is evolving rapidly
along with the identification of novel inducers, the understanding
of mechanisms regulating WNT-5A expression and homeostasis
remains poor. In this study, we have investigated the molecular
mechanisms involved in TGF-b-induced WNT-5A expression
using airway smooth muscle cells as model system.
TGF-b is a pleiotropic cytokine with functions as diverse as
embryonic development and maintenance of adult tissue homeo-
stasis to regulating stem cell renewal, cell fate determination and
cellular proliferation [23,24]. Binding of TGF-b to its receptors
leads to phosphorylation and dimerization of SMAD2/3 and
generation of a heterotrimeric complex with SMAD4 which
translocates to the nucleus and activates TGF-b-responsive genes.
Besides, TGF-b can signal in a SMAD-independent manner
through activation of TGF-b-activated kinase 1 (TAK1), p38,
extracellular signal-regulated kinases 1/2 (ERK1/2), JNK,
phosphatidylinositol 3-kinase (PI3K)/AKT, small Rho-GTPases
and Nuclear Factor kB (NFkB) to name a few [25].
TAK1, first identified as a mitogen-activated kinase kinase
kinase (MAP3K) activated by TGF-b, is a critical regulator in
inflammatory, immune and stress response signaling [26,27].
TAK1 constitutes an integral part of pro-inflammatory cytokine
signaling, activating NFkB and MAPK pathways [27]. Besides,
TAK1 also mediates the SMAD-independent arm of the TGF-b
signaling pathway and regulates various TGF-b-induced cellular
responses [27,28].
Here, we investigated the molecular mechanisms involved in
TGF-b-induced WNT-5A expression using airway smooth muscle
cells as 1] airway smooth muscle cells are key structural and
functional component of airways and major contributor of airway
remodeling in asthma and 2] TGF-b upregulates WNT-5A
expression in these cells. We examined the participation of various
TGF-b-activated pathways and demonstrate that TAK1 via p38
and JNK mediates WNT-5A expression. Further, we determined
an unanticipated role for b-catenin in WNT-5A expression and
describe its regulation by TAK1. Finally, we identify Sp1 as the
transcription factor for WNT-5A and demonstrate a link between
TAK1, b-catenin and Sp1.
Materials and Methods
Reagents
Recombinant human TGF-b1 and rat anti-WNT-5A antibody
were from R&D systems (Abingdon, UK). siRNAs specific for
human TAK1, human CUTL1, human TCF4 and human ETS1,
rabbit anti-Sp1 (PEP2) X TransCruz, mouse anti-GAPDH, mouse
anti-b-actin, horseradish peroxidase (HRP)-conjugated chicken
anti-rat antibody and Protein A-agarose were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-
phospho-Thr183/Tyr185-SAPK/JNK antibody and rabbit anti-
phospho-Thr180/Tyr182-p38 MAPK (D3F9) antibody were
obtained from Cell Signaling Technology (Beverly, MA, USA).
Mouse anti-total b-catenin antibody was from BD Biosciences
(San Jose, CA, USA) and mouse anti-active b-catenin antibody
(clone 8E7) was obtained from Millipore (Amsterdam, the
Netherlands). Cycloheximide, IGEPAL CA-630, HRP-conjugated
goat anti-mouse antibody and HRP-conjugated goat anti-rabbit
antibody were obtained from Sigma (St. Louis, MO, USA).
Human b-catenin and non-targeting siRNA were procured from
Qiagen (Venlo, the Netherlands). X-tremeGENE siRNA and X-
tremeGENE DNA HP transfection reagents were purchased from
Roche Applied Science (Mannheim, Germany). LL-Z1640-2 was
obtained from Bioaustralis (Smithfield, NSW, Australia). Y-27632
dihydrochloride, LY294002 hydrochloride, SB203580, SP600125
and Mithramycin A were from Tocris (Bristol, UK) and SIS3 and
Bisindolylmaleimide I (BIM) were purchased from Calbiochem
(La Jolla, CA, USA). All other chemicals were of analytical grade.
Cell culture
Three human airway smooth muscle cell lines, immortalized by
human telomerase reverse transcriptase (hTERT) [29] were used
for all the experiments. The primary cultured human airway
smooth muscle cells used to generate each hTERT immortalized
cell line were prepared as described previously [29]. All
procedures were approved by the Human Research Ethics Board
(University of Manitoba). hTERT-airway smooth muscle cell lines
were maintained on uncoated plastic dishes in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with antibiotics
(50 U/ml streptomycin, 50 mg/ml penicillin) and 10% (v/v) fetal
bovine serum (FBS). For each experiment, hTERT-airway smooth
muscle cell lines (airway smooth muscle cells) derived from two to
three different donors were used for repeated measurements. Cells
were serum-deprived in DMEM supplemented with antibiotics
and ITS (5 mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml
selenium) before each experiment. When applied, inhibitors were
added 30 min before the TGF-b stimulation.
siRNA transfection
Airway smooth muscle cells were grown to ,90% confluence in
6-well cluster plates and transfected with 200 pmol of specific
siRNA in serum and antibiotic free DMEM with X-tremeGENE
siRNA transfection reagent. Control transfections were performed
using a non-targeting control siRNA. After 6 hours of transfection,
medium was replaced with DMEM supplemented with antibiotics
and ITS for a period of 42 hours before TGF-b stimulation.
S33Y-b-catenin DNA transfection
Airway smooth muscle cells grown to ,90% confluence in 6-
well cluster plates were transfected with 1 mg of mutant S33Y-b-
catenin plasmid (AddGene plasmid 19286, AddGene public
repository, Cambridge, MA, USA) [30] in serum and antibiotic
free DMEM using X-tremeGENE HP DNA transfection reagent.
2 mg of Green Fluorescent Protein (GFP) expression vector was
transfected as control. After 6 hours of transfection, medium was
replaced with DMEM supplemented with antibiotics and 10% (v/
v) fetal bovine serum (FBS) for 18 hours. Cells were then serum-
deprived in DMEM supplemented with antibiotics and ITS for
24 hours before the TGF-b stimulation.
RNA isolation and real-time PCR
Total RNA was extracted using the Nucleospin RNAII kit
(Macherey-Nagel, Duren, Germany) as per the manufacturer’s
instructions. Equal amounts of total RNA were then reverse
transcribed using the Reverse Transcription System (Promega,
Madison, USA). 1 ml of 1:2 diluted cDNA was subjected to real-
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time PCR, which was performed with the Illumina Eco Personal
QPCR System (Westburg, Leusden, the Netherlands) using
FastStart Universal SYBR Green Master (Rox) from Roche
Applied Science (Mannheim, Germany). Real time PCR was
performed with denaturation at 94uC for 30 seconds, annealing at
59uC for 30 seconds and extension at 72uC for 30 seconds for 40
cycles followed by 10 minutes at 72uC. Real time PCR data was
analyzed using the comparative cycle threshold (Cq: amplification
cycle number) method. The amount of target gene was normalized
to the endogenous reference gene 18S ribosomal RNA (DCq).
Relative differences were determined using the equation 2(2DDCq).
Primers used to analyze gene expression are: WNT-5A Fwd 59-
GGGTGGGAACCAAGAAAAAT -39 and Rev 59- TGGAACC-
TACCCATCCCATA -39; TAK1 Fwd 59- CTTGGATGG-
CACCTGAAG -39 and Rev 59- CAGGCTCTCAATGGGCT-
TAG -39; Collagen IaI Fwd 59- AGCCAGCAGATCGAG-
AACAT -39 and Rev 59- TCTTGTCCTTGGGGTTCTTG -
39; Fibronectin Fwd 59- TCGAGGAGGAAATTCCAATG -39
and Rev 59- ACACACGTGCACCTCATCAT -39; b-catenin
Fwd 59- CCCACTAATGTCCAGCGTTT -39and Rev 59-
AATCCACTGGTGAACCAAGC -39; CUTL1 Fwd 59- GCT-
GTTGCTGGAGAAGAACC -39and Rev 59- GGTCTT-
TCCCTTTCCTCCTG -39; TCF4 Fwd 59-CGTAGACCC-
CAAAACAGGAA -39and Rev 59- TCCTGTCGTGATTGGG-
TACA -39; ETS1 Fwd 59- CCAATCCAGCTATGGCAGTT -
39and Rev 59- TTCCTCTTTCCCCATCTCCT -39; Sp1 Fwd
59- GGAGAGCAAAACCAGCAGAC -39 and Rev 59- AAGGT-
GATTGTTTGGGCTTG -39 and 18S rRNA Fwd 59- CGC-
CGCTAGAGGTGAAATTC -39and Rev 59- TTGGCAAAT-
GCTTTCGCTC -39.
In silico promoter analysis
WNT-5A promoter sequences for both the alternative promoters
A and B were derived from human chromosome 3 genome (NCBI
accession # NT_022517) in consultation with earlier reports [31–
33]. Sequences were screened to identify the putative transcription
factor binding sites using online program PROMO version 3
[34,35]. The parameters were set to detect only human
transcription factor binding sites with maximum matrix dissimi-
larity rate set at 5%.
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed using the SimpleChIP Enzymatic
Chromatin IP Kit (Agarose Beads) from Cell Signaling Technol-
ogy (Beverly, MA, USA) as per manufacturer’s instructions.
Briefly, 16107 airway smooth muscle cells were fixed in
formaldehyde to final concentration of 1% for 10 minutes and
then stopped by adding glycine. Cross-linked chromatin was
digested using Micrococcal nuclease at 37uC for 20 minutes
followed by a brief sonication to generate 200–500 bp DNA
fragments. Sheared chromatin was incubated with anti-Sp1 (PEP2)
X TransCruz reagent (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or normal rabbit antibody (IgG) as negative control and
precipitated using Protein G-agarose beads. Immunoprecipitated
chromatin complexes were washed sequentially in Low- and High-
salt wash buffers and protein-DNA cross-links were reversed in
presence of Proteinase K at 65uC for 4 hours. DNA fragments
were purified using the spin columns supplied in the kit as per
recommendations. 2 ml of DNA from each sample was used as a
template for PCR amplification. PCR was performed with
denaturation at 94uC for 30 seconds, annealing at 59uC for 30
seconds and extension at 72uC for 30 seconds for 40 cycles
followed by 10 minutes at 72uC using primers designed to amplify
the region encompassing putative Sp1 binding sites on WNT-5A
promoter A Fwd 59- ACAGGATCGCGTGGAAATCT -39and
Rev 59- GAAGCTGCCCACCTCCTC -39.
L-cell conditioned medium preparation
Control and WNT-3A conditioned medium from L-cells were
prepared as described previously [16].
Preparation of cell lysates
The whole cell extracts were either prepared as described
previously [16] using SDS lysis buffer or by direct lysis in 2X
Laemmli loading buffer.
Co-Immunoprecipitation
For co-immunoprecipitation assay, airway smooth muscle cells
were washed twice with ice-cold PBS and lysed in 1% IGEPAL
buffer (20 mM Tris-HCl pH7.5, 120 mM NaCl, 1% IGEPAL
CA-630, 2 mM EDTA, 1 mM EGTA, 10 mg/ml Leupeptin,
Aprotinin and Pepstatin, 1 mM NaF, 1 mM Na3VO4, 1 mM
PMSF and 1 mM b-glycerophosphate) on ice, scraped and
collected in a microfuge. The collected lysate was further
incubated at 4uC with constant rotation for 4 hours. Lysates were
then cleared by centrifugation at 18000 g for 10 min at 4uC and
supernatant was collected. Protein concentrations were measured
using the BCA assay (Pierce) and 500 mg of protein lysate was
incubated with 2 mg anti-Sp1 antibody overnight at 4uC.
Immunocomplexes were then incubated with 30 ml of Protein A-
agarose slurry for 4 hours with constant rotation at 4uC. Protein
A-agarose-bound immunocomplexes were precipitated by centri-
fugation at 4000 g for 5 min at 4uC and washed three times with
lysis buffer. Finally, 2X Laemmli buffer was added to the
precipitates and heated for 5 min at 95uC. The heated lysates
were cleared by centrifugation at 4000 g for 5 min, supernatant
collected and stored at 220uC until further use.
Western analysis
Protein samples were subjected to electrophoresis, transferred to
nitrocellulose membranes, and analyzed for the proteins of interest
using specific primary and HRP-conjugated secondary antibodies.
Bands were subsequently visualized using the G-box gel
documentation system (Syngene, Cambridge, UK) using enhanced
chemiluminescence reagents and were quantified by densitometry
using Genetools software.
Data Analysis
Values reported for all data are represented as mean 6 SEM.
The statistical significance of differences between means was
determined on log transformed data by Student’s t-test, by 1-way
ANOVA or by 2-way ANOVA, followed by Student-Newman
Keuls or Bonferroni multiple comparisons test, where appropriate.
Differences were considered to be statistically significant when
p,0.05.
Results
TAK1 mediates TGF-b-induced WNT-5A expression
TGF-b activates multiple pathways, both SMAD-dependent
and -independent, downstream of its receptor. We targeted key
pathways to identify the signaling cascades involved in WNT-5A
expression by TGF-b in airway smooth muscle cells. We observed
that pharmacological inhibition of SMAD3 (SIS3; 3 mM), Rho-
associated protein kinase (ROCK) (Y27632; 1 mM), PI3K
(LY294002; 3 mM), glycogen synthase kinase (GSK) -3
(SB216763; 10 mM) and PKC (BIM; 3 mM), failed to reduce
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WNT-5A induction by TGF-b (Figure S1A-E). Surprisingly, the
SMAD3 inhibitor SIS3 significantly increased WNT-5A mRNA
abundance by ,2-fold in comparison to both the basal and TGF-
b-stimulated conditions (Figure S1A) whereas GSK-3 inhibition by
SB216763 also lead to a modest but significant increase in WNT-
5A induction at the basal level (fold-induction 1.760.4) (Figure
S1D).
Notably, inhibition of TAK1 by LL-Z1640-2 attenuated WNT-
5A mRNA expression in a dose-dependent manner with
significant reduction at 0.5 mM and 1 mM by ,75% and
,91%, respectively (Figure 1A). Consistent with the mRNA data,
TAK1 inhibition also abrogated the TGF-b-induced increase in
WNT-5A protein expression (Figure 1B).
To further validate the role of TAK1 in WNT-5A induction, we
employed TAK1-specific siRNA. Transfection of airway smooth
muscle cells with TAK1 siRNA significantly repressed TAK1
transcripts to ,30% of the baseline expression in both the
unstimulated and TGF-b-stimulated airway smooth muscle cells in
comparison to non-targeting siRNA transfected cells (Figure 1C).
In agreement with the findings above using LL-Z1640-2, TAK1-
specific siRNA significantly attenuated TGF-b-induced increase in
abundance of WNT-5A transcripts by ,50% (Figure 1D).
We have previously reported a role for WNT-5A in TGF-b-
induced ECM production [16]. In line with that, both the
inhibition and knock-down of TAK1 reduced TGF-b-induced
ECM production, further confirming an upstream role for TAK1
in WNT-5A expression (Figure 1E, F).
Collectively, our data suggest that TAK1 specifically mediates
TGF-b-induced WNT-5A production.
TAK1-activated p38 and JNK signaling mediate TGF-b-
induced WNT-5A expression
Next, we investigated the signaling mechanisms downstream of
TAK1 activation which could be involved in WNT-5A induction
by TGF-b in airway smooth muscle cells. TAK1 activates JNK
and p38 pathways in multiple systems [27] which we sought to
confirm in airway smooth muscle cells. We found that TGF-b
induced activation of p38 and JNK, as indicated by their increased
phosphorylation status, which was attenuated in the presence of
the TAK1 inhibitor LL-Z1640-2 (Figure 2A). Next, we directly
targeted p38 and JNK kinases to assess their effect on WNT-5A
induction. Surprisingly, individual targeting of p38 (SB203580;
10 mM) and JNK (SP600125; 10 mM) by specific pharmacological
inhibitors failed to lower TGF-b-induced WNT-5A mRNA
expression (Figure 2B, C), whereas targeting p38 and JNK
signaling simultaneously lead to significant attenuation of TGF-b-
induced WNT-5A mRNA expression by ,60% (Figure 2D).
Our data therefore suggest that TAK1 mediates TGF-b-
induced p38 and JNK kinases activation which can redundantly
mediate the downstream effects of TAK1 on WNT-5A induction.
b-Catenin is involved in TGF-b-induced WNT-5A
expression
In order to further clarify the molecular mechanisms mediating
WNT-5A induction, we targeted protein translation to address
whether de novo protein synthesis is involved in TGF-b-induced
WNT-5A expression in airway smooth muscle cells. Interestingly,
while the presence of cycloheximide increased basal WNT-5A
mRNA abundance (fold-induction 2.260.26); it significantly
attenuated TGF-b-induced augmentation in WNT-5A transcript
levels by ,44% (Figure 3A).
We have earlier shown that TGF-b stabilizes the canonical
WNT signaling effector and transcriptional co-activator b-catenin
in airway smooth muscle cells which is affected by inhibition of de
novo protein synthesis [36]; therefore we investigated the involve-
ment of b-catenin in WNT-5A induction. Transfection of airway
smooth muscle cells with b-catenin-specific siRNA significantly
decreased the abundance of b-catenin transcripts in both the
unstimulated and TGF-b stimulated cells confirming an effective
knock-down (Figure 3B). Accordingly, b-catenin siRNA attenuated
TGF-b-induced WNT-5A mRNA expression by ,62% in
comparison to non-targeted siRNA-transfected cells (Figure 3C).
In accordance with the mRNA data, b-catenin knock-down
abrogated TGF-b-induced WNT-5A expression at protein level as
well (Figure 3D).
To further corroborate the role of b-catenin, we utilized
degradation-resistant constitutively active b-catenin mutant
(S33Y-b-catenin). This S33Y-b-catenin mutant has a serine to
tyrosine substitution at amino acid position 33 rendering it
unphosphorylatable by GSK-3 and therefore resistant to protea-
somal degradation. Transfection of airway smooth muscle cells
with S33Y-b-catenin lead to enhanced expression of total b-
catenin in the cell (Figure 3E). Interestingly, this was sufficient to
increase WNT-5A protein in the absence of TGF-b, remarkably
similar to the level of WNT-5A in control vector-transfected TGF-
b-treated cells (Figure 3E).
As b-catenin stabilization is a hallmark of canonical WNT
signaling activation, we hypothesized that canonical WNT
signaling can also increase WNT-5A expression. To test this
hypothesis, we stimulated airway smooth muscle cells with WNT-
3A conditioned medium. Remarkably, WNT-3A conditioned
medium led to a 2-fold induction in WNT-5A transcript levels in
airway smooth muscle cells when compared to control conditioned
medium (Figure 3F).
Our data therefore suggest a central role for b-catenin in WNT-
5A induction.
TAK1 signaling regulates b-catenin
Having confirmed the role of b-catenin, we got interested in the
link between TAK1 and b-catenin in WNT-5A expression. As
both TAK1 and b-catenin are required for WNT-5A induction,
we first investigated for possible cross-regulation. To address this,
Figure 1. TAK1 regulates TGF-b-mediatedWNT-5A induction in airway smooth muscle cells. (A, E) Airway smooth muscle cells were either
left unstimulated (vehicle basal) or stimulated with TGF-b (2 ng/ml) in the presence or absence of LL-Z1640-2 (0.1 mM, 0.5 mM, 1.0 mM) for 24 hours.
Expression of WNT-5A mRNA(A) and collagen IaI and fibronectin mRNA (E) was determined by qRT-PCR, corrected for 18S rRNA and expressed
relative to vehicle basal. Data represent mean 6 SEM of 4-5 independent experiments. **p,0.01, ***p,0.001 compared to vehicle basal, # p,0.05,
## p,0.01,### p,0.001 compared to TGF-b-stimulated cells; 2-way ANOVA followed by Bonferroni multiple comparisons test. (B) Airway smooth
muscle cells were stimulated with TGF-b (2 ng/ml) in the presence or absence of LL-Z1640-2 (0.5 mM) for 48 hours. Western analysis was performed
on whole cells extracts for WNT-5A protein. Expression of GAPDH was analyzed as loading control. (C–D, F) Airway smooth muscle cells were
transfected with TAK1-specific siRNA or a non-targeting siRNA as control. Subsequently, cells were stimulated with TGF-b (2 ng/ml) for 24 hours and
analyzed for the expression of TAK1 mRNA (C), WNT-5A mRNA (D) and collagen IaI and fibronectin mRNA (F) by qRT-PCR and expressed relative to
non-targeting siRNA-transfected, untreated control. Data represent mean 6 SEM of 4 independent experiments. *p,0.05, **p,0.01, ***p,0.001
compared to non-targeting siRNA-transfected untreated control, #p,0.05, ## p,0.01 compared to non-targeting siRNA-transfected, TGF-b-
stimulated cells; 1-way ANOVA followed by Newman-Keuls multiple comparisons test.
doi:10.1371/journal.pone.0094801.g001
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we studied b-catenin stability in the presence of LL-Z1640-2.
Interestingly, we observed that the TGF-b-induced increase in
total b-catenin abundance was significantly suppressed in the
presence of LL-Z1640-2 by ,68% (Figure 4A).
Next, we investigated whether p38 and JNK are involved in
TAK1-mediated b-catenin regulation. Of note, while JNK
inhibition had no effect, inhibition of p38 significantly attenuated
TGF-b-induced total b-catenin protein abundance by ,70% in
comparison to TGF-b in airway smooth muscle cells (Figure 4B).
Accordingly, simultaneous inhibition of both p38 and JNK
completely attenuated TGF-b-induced increase in total b-catenin
levels in airway smooth muscle cells (Figure 4C).
We were intrigued by the contrasting results that while b-
catenin is required for TGF-b-induced WNT-5A expression, the
reduction in total b-catenin by p38 inhibition, though substantial,
totally failed to affect WNT-5A transcript levels (Figure 2B and
4B). To address this issue, we focused on the functional fraction of
b-catenin - the non-phosphorylated or active b-catenin. We
observed that TGF-b induced non-phosphorylated active b-
catenin at 16 and 24 hours which were attenuated by the TAK1
inhibitor LL-Z1640-2 at both the 16 and 24 hours by ,74% and
,100%, respectively (Figure 4D, E). Notably, inhibition of p38 by
SB203580 failed to yield significant effect on the TGF-b-induced
Figure 2. TAK1-activated p38/JNK signaling regulates WNT-5A induction in airway smooth muscle cells. (A) TAK1 activates p38 and
JNK. Airway smooth muscle cells were stimulated with TGF-b (2 ng/ml) in the presence or absence of LL-Z1640-2 (0.5 mM) for 30 and 60 minutes.
Whole cells extracts were immunoblotted for phospho-p38 and phospho-JNK using specific antibodies. Equal protein loading was verified by the
analysis of b-actin. (B–D) p38 and JNK involvement in WNT-5A expression. Airway smooth muscle cells were stimulated with TGF-b (2 ng/ml) in the
presence or absence of SB203580 (10 mM) or SP600125 (10 mM) or combination of both SB203580 and SP600125 (10 mM each) for 24 hours. RNA was
isolated and WNT-5A mRNA expression was determined by qRT-PCR, corrected for 18S rRNA and expressed relative to vehicle basal. Data represent
mean 6 SEM of 4–6 independent experiments. **p,0.01, ***p,0.001 compared to vehicle basal, ### p,0.001 compared to TGF-b-stimulated
cells; 1-way ANOVA followed by Newman-Keuls multiple comparisons test.
doi:10.1371/journal.pone.0094801.g002
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Figure 3. b-Catenin mediates TGF-b-induced WNT-5A expression in airway smooth muscle cells. (A) De novo protein synthesis is required
for TGF-b-induced WNT-5A expression. Airway smooth muscle cells were either left unstimulated (vehicle basal) or stimulated with TGF-b (2 ng/ml) in
the presence or absence of the protein synthesis inhibitor cycloheximide (5 mg/ml) for 24 hours. WNT-5A mRNA induction was evaluated by qRT-PCR.
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increase in levels of active b-catenin at both the time points studied
(data not shown).
Collectively, our data suggest that TAK1 signaling mediates
regulation of b-catenin via p38 and JNK.
Sp1 is the transcription factor for WNT-5A
We next sought to determine the transcription factor(s)
employed by TGF-b to induce WNT-5A expression in airway
smooth muscle cells. WNT-5A has two alternative promoters-A
and B. To identify the potential transcription factors, we did in
silico analysis of both the human WNT-5A promoter A and B as
described in the Materials and Methods section which predicted
binding sites for various transcription factors on both the
promoters A (Figure 5A) and B (data not shown). Some of the
key transcription factors and their binding sites on promoter A are
presented in the diagram (Figure 5A). CUTL1 drives WNT-5A
expression in pancreatic cancer cell lines whereas TCF4 is the
most common transcriptional partner of b-catenin. Based on the
information from the promoter analysis, our own observations
from the role of b-catenin in WNT-5A induction and previous
reports about WNT-5A transcriptional regulation, we targeted
CUTL1, TCF4 and ETS1 using specific siRNAs. Interestingly,
while specific siRNAs substantially repressed the abundance of
CUTL1, TCF4 or ETS1 mRNAs confirming significant knock-
down efficiency (Figure 5B, D, F), WNT-5A induction remained
unaffected (Figure 5C, E, G).
Further scrutiny of WNT-5A promoter revealed multiple Sp1
binding sites on both the promoter A and B. To address Sp1
involvement in WNT-5A induction, we used Mithramycin A
which is a selective inhibitor of recruitment of Sp family of
transcription factors to the binding sites on promoter region.
Interestingly, treatment with Mithramycin A (300 nM) totally
abrogated TGF-b-induced expression of WNT-5A mRNA
(Figure 6A). Accordingly, Mithramycin A also attenuated TGF-
b-induced augmentation in WNT-5A protein abundance
(Figure 6B).
To further validate the role of Sp1 in WNT-5A induction, we
employed Sp1-specific siRNA. Transfection of specific siRNA
significantly repressed Sp1 transcripts in both the unstimulated
and TGF-b-stimulated airway smooth muscle cells in comparison
to non-targeting siRNA transfected cells (Figure 6C). In agreement
with the observations above using Mithramycin A, Sp1-specific
siRNA significantly attenuated TGF-b-induced increase in abun-
dance of WNT-5A transcripts confirming the requirement for Sp1
in WNT-5A induction (Figure 6D).
In line with the requirement of WNT-5A in TGF-b-induced
ECM expression, we checked whether Sp1 inhibition shows
similar effects. Interestingly, inhibition of Sp1 activity by
Mithramycin A attenuated TGF-b-induced expression of collagen
IaI and fibronectin (Figure 6E), further underlining the role of Sp1
in WNT-5A induction.
We next performed chromatin immunoprecipitation (ChIP)
assay and validated the direct binding of Sp1 to WNT-5A
promoters. Consistent with the role of Sp1 in WNT-5A induction
as deduced from Mithramycin A and Sp1 siRNA, we confirmed
binding of Sp1 on WNT-5A promoter A in response to TGF-b
(Figure 6F). Of note, while the recruitment of Sp1 on WNT-5A
promoter A was induced by TGF-b, Sp1 occupancy of promoter B
was TGF-b independent (data not shown). In line with the role of
TAK1 in WNT-5A induction, the TGF-b-induced Sp1 recruit-
ment to WNT-5A promoter A was abrogated in the presence of
TAK1 inhibitor LL-Z1640-2 (Figure 6G)
Our data, therefore, suggest that Sp1 is required for WNT-5A
expression and is recruited to WNT-5A promoter via TAK1 in
response to TGF-b in airway smooth muscle cells.
TGF-b promotes b-catenin/Sp1 interaction
As we observed that both Sp1 and b-catenin are required for
WNT-5A induction via TAK1, we sought to investigate the
functional link between these findings. b-Catenin can function as
transcriptional co-activator and partner with various transcription
factors to regulate gene expression. We therefore determined
whether b-catenin physically interacts with Sp1. Indeed, a co-
immunoprecipitation assay using whole cell extracts from airway
smooth muscle cells demonstrated that Sp1 associates with b-
catenin (Figure 7). Interestingly, this Sp1/b-catenin interaction
was further enhanced by TGF-b as indicated by increased
amounts of b-catenin in Sp1 immunoprecipitates from TGF-b-
stimulated cells (Figure 7). Of note, the increased interaction
between Sp1 and b-catenin coincides with increased abundance of
b-catenin by TGF-b as seen in whole cell extracts while Sp1 levels
remain fairly equal (Figure 7).
In summary, our data demonstrate that TGF-b promotes b-
catenin/Sp1 interaction.
Discussion
In the present study, we have delineated the signaling
mechanisms driving TGF-b-induced WNT-5A expression in
airway smooth muscle cells. To the best of our knowledge, this
is the first report describing a signaling cascade consisting of
TAK1, b-catenin and Sp1 that regulates WNT-5A expression. We
demonstrate that TAK1 activity is required for WNT-5A
expression in response to TGF-b stimulation and provide evidence
for the involvement of b-catenin in this process which, in turn, is
regulated by TAK1 signaling. We further identify Sp1 as
transcription factor for WNT-5A and demonstrate its interaction
with b-catenin in airway smooth muscle cells. We provide
evidence that Sp1 is recruited to the WNT-5A promoter in
Data represent mean 6 SEM of 4 independent experiments. **p,0.01, ***p,0.001 compared to vehicle basal, ## p,0.01 compared to TGF-b-
stimulated cells; 2-tailed Student’s t test for paired observations. (B-D) b-Catenin silencing reduces TGF-b-induced WNT-5A expression. Airway smooth
muscle cells were transfected with b-catenin-specific siRNA or a non-targeting siRNA as control. Subsequently, cells were stimulated with TGF-b
(2 ng/ml) for 24 hours (mRNA; B,C) or 48 hours (protein; D). (B,C) Expression of b-catenin mRNA (B) and WNT-5A mRNA (C) was determined by qRT-
PCR and expressed relative to non-targeting siRNA transfected, untreated control. Data represent mean 6 SEM of 5 independent experiments.
*p,0.05, **p,0.01 compared to non-targeting siRNA-transfected, untreated control, # p,0.05, ### p,0.001 compared to non-targeting siRNA-
transfected, TGF-b-stimulated cells; 2-tailed Student’s t test for paired observations. (D) Western blot analysis was performed to analyze WNT-5A and
b-catenin protein expression in whole cell extracts. Equal protein loading was verified by the analysis of GAPDH. (E) Forced increase in b-catenin
abundance elevates WNT-5A protein level. Cells were transfected with S33Y-b-catenin mutant or a GFP expression vector as control. Subsequently,
cells were either left untreated or stimulated with TGF-b (2 ng/ml) for 48 hours. Western blot analysis was performed to determine the abundance of
WNT-5A and total b-catenin at protein level. GAPDH expression assessed as loading control. (F) Canonical WNT ligand stimulation increases WNT-5A
gene expression. Cells were stimulated with L-cells-derived WNT-3A conditioned medium or control conditioned medium for 24 hours. Expression of
WNT-5A mRNA was evaluated by qRT-PCR and expressed relative to control conditioned medium. Data represent mean 6 SEM of 5 independent
experiments. **p,0.01 compared to control conditioned medium; 2-tailed Student’s t test for paired observations.
doi:10.1371/journal.pone.0094801.g003
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response to TGF-b, a phenomenon regulated by TAK1 activity.
Collectively, our study identifies a novel pathway involved in
WNT-5A regulation, thus, providing an understanding of
mechanisms governing WNT-5A homeostasis.
WNT-5A plays a key role in wide range of developmental and
postnatal processes and derailed WNT-5A homeostasis has been
widely implicated in myriad of pathological situations [9]. WNT-
5A expression is induced by a variety of growth factors and
cytokines, however, little is known about the mechanisms
regulating WNT-5A expression. Here, we demonstrate that
TAK1 mediates WNT-5A expression in response to TGF-b as
pharmacological inhibition or siRNA mediated silencing of TAK1
suppressed the TGF-b-induced augmentation in WNT-5A
expression. Interestingly, out of many targeted TGF-b-activated
pathways including the SMAD3-dependent cascade, only TAK1
inhibition was able to attenuate TGF-b-induced WNT-5A
expression. This suggests that TAK1-mediated induction of
WNT-5A is a highly selective phenomenon. TAK1 inhibition or
siRNA also attenuated TGF-b induced ECM gene expression,
demonstrating the functional importance of TAK1 in this
response.
MAPKs including p38 and JNK are downstream effectors of
TAK1 in many cell types [27]. A study from our group has shown
that TAK1 mediates PDGF-induced ERK1/2 activation in airway
smooth muscle cells [37]. Here, we show that TAK1 mediates
TGF-b-induced activation of p38 and JNK MAPKs in airway
smooth muscle cells as demonstrated by the inhibitory effect of LL-
Z1640-2. We further provide evidence for direct involvement of
p38 and JNK signaling in WNT-5A induction. Remarkably, only
simultaneous but not separate inhibition of p38 and JNK could
reduce TGF-b-induced WNT-5A expression. This clearly suggests
that p38 and JNK redundantly regulate TGF-b-induced WNT-5A
expression in airway smooth muscle cells.
TGF-b/SMAD constitutes the principle signaling axis in TGF-
b responses [23]. We observed that the inhibition of SMAD3
enhanced TGF-b-induced WNT-5A expression, indicating a
negative regulation by SMAD pathway. The contribution of
TGF-b/SMAD signaling in WNT-5A induction, therefore, cannot
be ruled out. Further investigation is required to decipher the
regulatory role and underlying mechanisms of SMAD signaling in
TGF-b-induced WNT-5A expression.
b-Catenin, the canonical WNT signaling effector, constitutes an
important component in TGF-b signaling in airway smooth
muscle cells [38]. In canonical WNT signaling, cytosolic b-catenin
is continuously phosphorylated by a multi-component destruction
complex comprising of GSK-3 and marked for proteasomal
degradation. Inactivation of destruction complex by canonical
WNT ligands rescues b-catenin, leading to its accumulation in
cytosol. Free cytosolic b-catenin then translocates to the nucleus
and activates gene transcription [1]. Besides canonical WNT
ligand, TGF-b also stabilizes b-catenin where it participates in
TGF-b-specific cellular responses [38]. Our group has previously
identified important physiological and functional roles for b-
catenin in airway smooth muscle cells [36,39–41]. Here, we
describe a novel role for b-catenin in WNT-5A induction.
Silencing of b-catenin reduced TGF-b-induced WNT-5A induc-
tion. In addition to that, transient transfection of degradation
resistant S33Y-b-catenin mutant in airway smooth muscle cells
raised the basal WNT-5A protein abundance underlining the
importance of b-catenin in WNT-5A induction. Remarkably, the
presence of the canonical WNT ligand- WNT-3A also modestly
augmented WNT-5A transcription, raising the possibility that b-
catenin stabilization constitutes a primary phenomenon in WNT-
5A expression in airway smooth muscle cells. However, WNT-3A-
induced WNT-5A expression was much weaker in comparison to
TGF-b-mediated induction suggesting that pathways other than
stable b-catenin, define the magnitude of WNT-5A expression
levels.
TGF-b engages a two pronged mechanism to increase the
cytosolic abundance of b-catenin in airway smooth muscle cells-
first, it inactivates GSK-3, the key upstream mediator of b-catenin
degradation and second, it induces transcriptional upregulation of
b-catenin [38]. Here, we demonstrate TAK1-mediated stabiliza-
tion and subsequent increase in b-catenin abundance in response
to TGF-b. Using LL-Z1640-2, we show that the TGF-b-induced
increase in total cytosolic b-catenin levels is attenuated on TAK1
inhibition. This is in line with a recent report showing the positive
effect of TAK1 on b-catenin stabilization and nuclear localization
in KRAS-dependent colon cancer cells [42]. Furthermore, we
extend our findings by demonstrating that TAK1 inhibition
reduces transcriptionally active non-phosphorylated b-catenin,
linking the TAK1-mediated regulation of b-catenin to functional
level. The downstream mediators of TAK1 signaling- p38 and
JNK- redundantly mediate b-catenin regulation in response to
TGF-b. Interestingly, we also observed that TAK1 activity
mediates TGF-b-induced GSK-3 inactivation by phosphorylation
at Ser9-GSK-3a and Ser21-GSK-3b (data not shown). The
observed GSK-3 phosphorylation sites are targeted by PI3K/
AKT signaling [43] indicating the possible activation of PI3K/
AKT by TAK1 in response to TGF-b. Indeed, TGF-b has been
shown to activate AKT pathway via TAK1 signaling [44].
Multiple signaling pathways activated by TAK1 explain the
redundancy we observe in TAK1 signaling with respect to WNT-
5A induction. Altogether, our study identifies TAK1 as an
upstream regulator of b-catenin, mediating its effects via a
signaling cascade comprising of GSK-3, p38 and JNK. As PI3K
inhibition failed to alter WNT-5A abundance, the relative
contributions of GSK-3 and p38/JNK in b-catenin stabilization
and WNT-5A expression warrant further investigation.
Altered expression patterns of WNT-5A and b-catenin have
been implicated in various disorders, for instance, fibrosis.
Enhanced expression and increased nuclear localization of b-
Figure 4. TAK1 regulates total and active fraction of b-catenin in airway smooth muscle cells. (A-C) TAK1 signaling in total b-catenin
regulation. Airway smooth muscle cells were either left unstimulated (vehicle basal) or stimulated with TGF-b (2 ng/ml) in the presence or absence of
LL-Z1640-2 (0.5 mM), SB203580 (10 mM), SP600125 (10 mM) or the combination of SB203580 and SP600125 (10 mM each) for 24 hours. Whole cell
extracts were subjected to western analysis for detection of total b-catenin protein abundance. GAPDH expression was examined as loading control.
Graphs represent quantitation of band intensities for total b-catenin corrected for GAPDH as percentage of TGF-b-induced expression. Data represent
mean 6 SEM of 4-6 independent experiments. *p,0.05, **p,0.01 compared to vehicle basal, # p,0.05, ## p,0.01 compared to TGF-b-stimulated
cells; 2-tailed Student’s t test for paired observations. (D, E) Regulation of active b-catenin by TAK1. Airway smooth muscle cells were either left
unstimulated (vehicle basal) or stimulated with TGF-b (2 ng/ml) in the presence or absence of LL-Z1640-2 (0.5 mM) for 16 or 24 hours as indicated.
Whole cells extracts were subjected to western analysis for detection of active b-catenin protein abundance. Expression of GAPDH was assessed as
loading control. Graphs represent quantitation of band intensities for active b-catenin corrected for loading control as percentage of TGF-b-induced
expression. Data represent mean 6 SEM of 5 independent experiments. *p,0.05, **p,0.01 compared to vehicle basal, # p,0.05, ## p,0.01
compared to TGF-b-stimulated cells; 2-tailed Student’s t test for paired observations.
doi:10.1371/journal.pone.0094801.g004
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catenin have been shown in idiopathic pulmonary fibrosis (IPF)
[45,46], systemic sclerosis [47] and has also been linked to liver
[48] and renal fibrosis [49]. Similarly, increased WNT-5A
expression levels have also been linked to lung [11], hepatic [13]
and renal [12] fibrosis. Recently, two separate studies from our lab
have also shown that WNT-5A and b-catenin mediate common
function in TGF-b signaling in the airway smooth muscle cells
[16,39]. We have shown that TGF-b-induced WNT-5A mediates
ECM production in airway smooth muscle cells [16] whereas
another report shows that b-catenin is required and sufficient to
induce ECM production in airway smooth muscle cells, even in
the absence of TGF-b [39,50]. Paradoxically, WNT-5A has been
shown to both activate and antagonize b-catenin signaling in a
receptor-specific manner [51]. We have previously demonstrated
WNT-independent regulation of TGF-b-induced b-catenin, as
neither silencing of WNT-5A nor inhibition of WNT ligand
secretion by IWP2 could alter TGF-b-induced b-catenin abun-
dance in airway smooth muscle cells [16]. However, our current
study provides the unanticipated but functional explanation
connecting b-catenin as an upstream mediator of WNT-5A
induction in airway smooth muscle cells. Together with the
previous studies, our data suggest a complex cell-dependent
relation between b-catenin and WNT-5A.
Transcriptional upregulation of WNT-5A has been reported in
several studies. The WNT-5A gene generates two very identical
transcripts by utilization of alternative transcription start sites of
which the corresponding upstream sequences are termed as
promoter A and B [32,33]. Both the promoters have comparable
transcriptional potential; their activity, however, is highly context
dependent. For instance, WNT-5A promoter A has been suggested
to be more active in human and murine fibroblasts [33]. CUTL1
[17], STAT3 [52], TBX1 [53], NFkB [18,19] have all previously
been reported as transcription factors for WNT-5A in various cell
types. We performed in silico analysis of WNT-5A promoters which
revealed multiple putative transcription factor binding sites on
both the promoters. Our WNT-5A promoter screen predicted
previously described transcription factor binding sites underlining
its accuracy. Silencing of CUTL1 or ETS1 failed to affect WNT-
5A induction in airway smooth muscle cells suggesting a cell-
specific transcriptional program regulating WNT-5A expression.
Our observations regarding involvement of b-catenin in WNT-5A
induction lead us to target TCF4, the most common binding
partner of b-catenin. However, TCF4 knock-down didn’t effect
WNT-5A induction in our system suggesting that b-catenin does
not utilize TCF4 for mediating WNT-5A induction.
Sp1, a member of Specificity protein/Kruppel-like family of
transcription factors, is ubiquitously expressed and involved in
regulating expression of a wide array of genes starting from early
embryonic phase and extending throughout the life span [54].
TGF-b utilizes Sp1 for mediating many of its transcriptional
responses [54]. Multiple putative Sp1 transcription factor binding
sites on WNT-5A promoter have been predicted earlier [31,33]
and also appeared in our WNT-5A promoter screen. We used
Mithramycin A and specific siRNA to deduce the role of Sp1 in
WNT-5A induction. Mithramycin A is a highly selective inhibitor
of Sp1 which competes for DNA binding with Sp1 and attenuates
its recruitment on promoters [55]. Interestingly, pharmacological
inhibition of Sp1 by Mithramycin A or Sp1 knock-down using
specific-siRNA significantly attenuated TGF-b-induced WNT-5A
expression confirming a vital role for Sp1 in this process.
Mithramycin A also attenuated ECM gene expression in response
to TGF-b, demonstrating the functional relevance of Sp1 in
WNT-5A mediated responses in airway smooth muscle cells. ChIP
analysis further validated the crucial role for Sp1 in WNT-5A
induction where we demonstrate direct binding of Sp1 on WNT-
5A promoter in TGF-b-dependent manner. Furthermore, we
identified TAK1 as upstream regulator of TGF-b-induced
recruitment of Sp1 as LL-Z1640-2 treatment reduced Sp1 binding
to WNT-5A promoter in airway smooth muscle cells. This is in
contrast with earlier reports where TAK1 has been shown to
negatively regulate Sp1 activity in keratinocytes and lung
adenocarcinoma cells [56,57]. However, our data firmly supports
positive interaction between Sp1 and TAK1 as inhibition of Sp1
completely abrogated WNT-5A expression, an effect which is
strikingly similar to inhibition of TAK1. This ambiguity in
observations underlines the context-dependent regulation of Sp1
by TAK1.
Sp1 activity is influenced by multiple post-translational modi-
fications governing its DNA binding activity and protein stability
[58]. MAPKs including p38 and JNK can regulate Sp1 via
phosphorylation. A study has reported association of Sp1 with p38
in fibroblasts leading to subsequent phosphorylation and increased
recruitment of Sp1 to filamin A promoter [59]. Similarly, LPS-
activated p38 regulates Sp1 binding to human il-10 promoter in
human monocytes [60] whereas it regulates Sp1 transactivation,
and not DNA binding, on platelet-activating factor acetylhydrolase (PAF
AH) promoter in murine and human immune cells [61]. Likewise,
JNK-mediated phosphorylation regulates Sp1 binding on human
urokinase-type plasminogen activator (uPA) gene promoter [62] and
regulates Sp1 protein stability during mitosis [63]. Sp1, hence, can
be differentially regulated by MAPK signaling, not only in a cell-
and stimulus-specific manner but also in a promoter-specific
manner. Consistent with the positive regulation of Sp1 by both
p38 and JNK signaling, activation of either p38 or JNK cascade is
sufficient to sustain TGF-b-induced and TAK1-mediated tran-
scriptional upregulation of WNT-5A. Our data, thus, suggest that
TAK1 signaling recruits Sp1 to WNT-5A promoter via activation
of p38 and JNK. Of note, this observation also provides an
explanation to the stimulatory effect of TAK1 on Sp1 in our
system as opposed to the inhibitory effect of TAK1 on Sp1 activity
as reported by other groups.
Both b-catenin and Sp1 can associate with various transcription
factors and co-activators in a cell- and stimulus-dependent manner
to mediate their cellular responses. However, the interaction
between b-catenin and Sp1 has been shown to be counteractive
and indirect. For instance, constitutive activation of WNT/b-
catenin signaling in mouse brain represses Sp1 target gene
expression via upregulation of Sp5, a Sp1 repressor protein [64].
On the other hand, Sp1 antagonizes b-catenin signaling by
enhancing expression of E-cadherin which sequesters b-catenin to
Figure 5. Evaluating transcriptional factors for theWNT-5A gene. (A) In silico analysis of WNT-5A promoter. Schematic representation of WNT-
5A promoter A indicating the transcription factor binding sites as predicted by PROMO version 3. Only selective transcription factors are depicted
here. The schematic is not to scale. TSS: Transcriptional Start Site. (B–G) Silencing of various transcription factors and WNT-5A gene expression. Airway
smooth muscle cells were transfected with a non-targeting siRNA as control or with CUTL1-specific (B, C), TCF4-specific (D, E) or ETS1-specific (F, G)
siRNA. Subsequently, cells were stimulated with TGF-b (2 ng/ml) for 24 hours and analyzed for the expression of genes as indicated in panels by qRT-
PCR, corrected for 18S rRNA and expressed relative to non-targeting siRNA transfected, untreated control. Data represent mean 6 SEM of 3-5
independent experiments. *p,0.05, **p,0.01, ***p,0.001 compared to non-targeting transfected, untreated control; 1-way ANOVA followed by
Newman-Keuls multiple comparisons test.
doi:10.1371/journal.pone.0094801.g005
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the membrane [65]. Here, we report a previously undetected
interaction between Sp1 and b-catenin in airway smooth muscle
cells which is further promoted by TGF-b suggesting a positive
functional role in TGF-b cellular responses. Of note, the increased
Sp1/b-catenin interaction as observed in the presence of TGF-b
coincides with increased cellular abundance of b-catenin. Whether
the Sp1/b-catenin interaction is spontaneous and determined by
the amount of cytosolic b-catenin available in the cell or is
influenced by external factors like TGF-b has yet to be
determined.
In airway smooth muscle cells, TAK1 mediates cell phenotype
and cigarette smoke-induced inflammation. A study from our
group has shown that TAK1-mediates PDGF induced activation
of ERK1/2, leading to airway smooth muscle cell proliferation
and reduction in contractile proteins [37]. Pera et al also identified
a pro-inflammatory role for TAK1 wherein it mediates cigarette
smoke-induced release of IL-8 in airway smooth muscle cells [66].
Interestingly, WNT-5A is a key player in pro-inflammatory
responses in both the immune and non-immune cells. For
instance, WNT-5A is induced by LPS/IFNc in human macro-
phages where it mediates release of pro-inflammatory cytokines
IL-8, IL-6, IL-1b and MIP-1b [20]. Similarly, WNT-5A induces
macrophage activation and release of IL-8 and CXC chemokines
in human monocytes [67]. Of note, WNT-5A also mediates pro-
inflammatory responses in human aortic endothelial cells, a non-
immune class of cells [68]. Our current findings correlating TAK1
activity and WNT-5A expression provide evidence for their close
interaction to mediate pro-inflammatory reactions.
In conclusion, our present study describes a novel signaling
cascade comprising of TAK1, b-catenin and Sp1 in TGF-b-
induced WNT-5A expression in airway smooth muscle cells. We
deduce the molecular pathway regulating WNT-5A expression
which can have implications in various physiological and
pathological situations involving WNT-5A. Moreover, our study
also provides a mechanistic insight intertwining TAK1, b-catenin
and Sp1 which, perhaps, has a much wider applicability extending
to other cell- and tissue types and processes involving these factors.
Our data suggest that TAK1 regulates TGF-b-induced WNT-5A
expression by two simultaneous but linked mechanisms – 1] it
augments expression of b-catenin which, in turn, partners with
Sp1, perhaps, finalizing a transcriptional complex and 2] it
promotes binding of Sp1 transcriptional complex to WNT-5A
promoter thereby allowing WNT-5A transcription. Interestingly,
therapeutic tools for targeting TAK1 [26] and Sp1 [58] are
available whereas small molecule inhibitors for b-catenin [1] and
WNT-5A [69] with therapeutic potential are fast emerging. Our
study, thus, not only sheds light on the regulatory mechanisms of
WNT-5A expression but also provides multiple therapeutic targets
which could be utilized to devise effective treatment strategies for
wide array of diseases involving this pathway.
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Figure S1 Signaling cascades in TGF-b-induced WNT-5A
expression. (A-E) Airway smooth muscle cells were either left
unstimulated (vehicle basal) or stimulated with TGF-b (2 ng/ml)
in the presence or absence of SIS3 (3 mM), Y27632 (1 mM),
LY294002 (3 mM), SB216763 (10 mM) or BIM (3 mM) for
24 hours. Expression of WNT-5A mRNA was determined by
qRT-PCR, corrected for 18S rRNA and expressed relative to
vehicle basal. Data represent mean 6 SEM of 3-8 independent
experiments. *p,0.05, **p,0.01, ***p,0.001 compared to
vehicle basal, # p,0.05, ## p,0.01, ### p,0.001 compared
to TGF-b-stimulated cells; 1-way ANOVA followed by Newman-
Keuls multiple comparisons test.
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Figure 6. Sp1 is the transcription factor for TGF-b-induced WNT-5A expression in airway smooth muscle cells. (A-B) Mithramycin A
attenuates WNT-5A mRNA and protein expression. (A) Cells were stimulated with TGF-b (2 ng/ml) in the presence or absence of Mithramycin A
(300 nM) for 24 hours. WNT-5A mRNA was analyzed by qRT-PCR. Data represent mean6 SEM of 4 independent experiments. **p,0.01 compared to
vehicle basal, ## p,0.01 compared to TGF-b-stimulated cells; 1-way ANOVA followed by Newman-Keuls multiple comparisons test. (B) Cells were
stimulated with TGF-b (2 ng/ml) in the presence or absence of Mithramycin A (300 nM) for 48 hours. Whole cell extracts were prepared and WNT-5A
protein abundance was evaluated by western analysis. GAPDH was assessed as loading control. (C, D) Cells were transfected with Sp1-specific or a
non-targeting siRNA as control. Subsequently, cells were stimulated with TGF-b (2 ng/ml) for 24 hours and analyzed for the expression of Sp1 mRNA
(C) and WNT-5A mRNA (D) by qRT-PCR. Data represent mean6 SEM of 5 independent experiments. *p,0.05, ***p,0.001 compared to non-targeting
siRNA-transfected untreated control, #p,0.05, ### p,0.001 compared to non-targeting siRNA-transfected, TGF-b-stimulated cells; 1-way ANOVA
followed by Newman-Keuls multiple comparisons test. (E) Mithramycin A attenuates TGF-b-induced extracellular matrix expression. Cells were
stimulated with TGF-b (2 ng/ml) in the presence or absence of Mithramycin A (300 nM) for 24 hours. Collagen IaI and fibronectin mRNA was analyzed
by qRT-PCR. Data represent mean 6 SEM of 4 independent experiments. *p,0.05, **p,0.01 compared to vehicle basal, #p,0.05, ## p,0.01
compared to TGF-b-stimulated cells; 1-way ANOVA followed by Newman-Keuls multiple comparisons test. (F) Sp1 is recruited to WNT-5A promoter in
response to TGF-b. Cells were left untreated or stimulated with TGF-b (2 ng/ml) for 16 hours. Chromatin was prepared and ChIP analysis was
performed as described in the Materials and Methods section. PCR was carried out using primers specific for Sp1 binding region on WNT-5A promoter
A after immunoprecipitation with anti-Sp1 or control IgG antibody. Input DNA from chromatin preparation before immunoprecipitation was
amplified to ascertain the loading. Resulting PCR products were analyzed by DNA PAGE. (G) TAK1 mediates recruitment of Sp1 to WNT-5A promoter
in response to TGF-b. Cells were left untreated or stimulated with TGF-b (2 ng/ml) in the presence or absence of LL-Z1640-2 (0.5 mM) for 16 hours.
ChIP analysis was performed as described above.
doi:10.1371/journal.pone.0094801.g006
Figure 7. TGF-b facilitates Sp1/b-catenin interaction. Airway
smooth muscle cells were stimulated with TGF-b (2 ng/ml) for 16 hours.
Co-immunoprecipitation was performed as described in the Materials
and Methods section. Immunocomplexes and whole cell extracts (WCE)
were subjected to western analysis as indicated in the panels.
doi:10.1371/journal.pone.0094801.g007
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